235 related articles for article (PubMed ID: 27790001)
1. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis.
Mihara M; Ohsugi Y; Kishimoto T
Open Access Rheumatol; 2011; 3():19-29. PubMed ID: 27790001
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases.
Ohsugi Y
Biol Pharm Bull; 2007 Nov; 30(11):2001-6. PubMed ID: 17978466
[TBL] [Abstract][Full Text] [Related]
3. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis.
Hashizume M; Mihara M
Arthritis; 2011; 2011():765624. PubMed ID: 22046525
[TBL] [Abstract][Full Text] [Related]
4. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
5. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis.
Srirangan S; Choy EH
Ther Adv Musculoskelet Dis; 2010 Oct; 2(5):247-56. PubMed ID: 22870451
[TBL] [Abstract][Full Text] [Related]
6. The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis.
Ohsugi Y; Kishimoto T
Expert Opin Biol Ther; 2008 May; 8(5):669-81. PubMed ID: 18407769
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production.
Hashizume M; Uchiyama Y; Horai N; Tomosugi N; Mihara M
Rheumatol Int; 2010 May; 30(7):917-23. PubMed ID: 19639319
[TBL] [Abstract][Full Text] [Related]
8. 1,25-dihydroxy Vitamin D3 and Interleukin-6 Blockade Synergistically Regulate Rheumatoid Arthritis by Suppressing Interleukin-17 Production and Osteoclastogenesis.
Kim H; Baek S; Hong SM; Lee J; Jung SM; Lee J; Cho M; Kwok SK; Park SH
J Korean Med Sci; 2020 Feb; 35(6):e40. PubMed ID: 32056400
[TBL] [Abstract][Full Text] [Related]
9. IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel FcγRIIB-deficient rheumatoid arthritis mouse model.
Ohtsuji M; Lin Q; Nishikawa K; Ohtsuji N; Okazaki H; Tsurui H; Amano H; Shirai T; Nishimoto N; Nishimura H; Hirose S
Mod Rheumatol; 2015 Mar; 25(2):270-7. PubMed ID: 25159156
[TBL] [Abstract][Full Text] [Related]
10. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.
Lubberts E; Koenders MI; Oppers-Walgreen B; van den Bersselaar L; Coenen-de Roo CJ; Joosten LA; van den Berg WB
Arthritis Rheum; 2004 Feb; 50(2):650-9. PubMed ID: 14872510
[TBL] [Abstract][Full Text] [Related]
11. Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis.
van Nieuwenhuijze AE; van de Loo FA; Walgreen B; Bennink M; Helsen M; van den Bersselaar L; Wicks IP; van den Berg WB; Koenders MI
Arthritis Res Ther; 2015 Jun; 17(1):163. PubMed ID: 26081345
[TBL] [Abstract][Full Text] [Related]
12. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
[TBL] [Abstract][Full Text] [Related]
13. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.
Diaz-Torne C; Ortiz MDA; Moya P; Hernandez MV; Reina D; Castellvi I; De Agustin JJ; Fuente D; Corominas H; Sanmarti R; Zamora C; Cantó E; Vidal S
Semin Arthritis Rheum; 2018 Jun; 47(6):757-764. PubMed ID: 29157669
[TBL] [Abstract][Full Text] [Related]
14. [IL-6 inhibitors prevent bone loss and cartilage degeneration in rheumatoid arthritis].
Murakami M; Nishimoto N
Clin Calcium; 2015 Dec; 25(12):1851-7. PubMed ID: 26608861
[TBL] [Abstract][Full Text] [Related]
15. Review of tocilizumab in the treatment of rheumatoid arthritis.
Okuda Y
Biologics; 2008 Mar; 2(1):75-82. PubMed ID: 19707430
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis.
Cronstein BN
Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S11-5. PubMed ID: 17708739
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights.
Hashizume M; Tan SL; Takano J; Ohsawa K; Hasada I; Hanasaki A; Ito I; Mihara M; Nishida K
Int Rev Immunol; 2015 May; 34(3):265-79. PubMed ID: 25099958
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab for the treatment of rheumatoid arthritis.
Mima T; Nishimoto N
Expert Rev Clin Immunol; 2008 Mar; 4(2):165-72. PubMed ID: 20477048
[TBL] [Abstract][Full Text] [Related]
19. [Humanized anti-human IL-6 receptor antibody, tocilizumab].
Nishimoto N
Nihon Rinsho; 2007 Jul; 65(7):1218-25. PubMed ID: 17642235
[TBL] [Abstract][Full Text] [Related]
20. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases.
Ding C; Jones G
Rev Recent Clin Trials; 2006 Sep; 1(3):193-200. PubMed ID: 18473972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
